FPF. Xavier Pi-Sunyer

F. Xavier Pi-Sunyer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


F. Xavier Pi-Sunyer has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Changes in body composition and metabolic disease risk

    by Xavier Pi-Sunyer

    As individuals gain weight, they increase the amount of fat that they accrue on their body. This causes adipocytes to enlarge and increases not only subcutaneous fat but also deposits fat in other vulnerable areas of the body. This ectopic fat is deposited in the intra-abdominal visceral fat depot, in muscle, in the liver and in the beta cells. Fat in these locations initiates a dysfunctional state in these insulin-sensitive tissues leading to insulin resistance, the appearance of the Metabolic Syndrome, and an increased risk of developing both type 2 diabetes and cardiovascular disease. A loss of weight and with it a loss of fat decreases this risk.


  • Open Access

    The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical Trial

    by Karen C Johnson, George A Bray, Lawrence J Cheskin, Jeanne M Clark, Caitlin M Egan, John P Foreyt, Katelyn R Garcia, Stephen Glasser, Frank L Greenway, Edward W Gregg, et al.

    Intentional weight loss is an important treatment option for overweight persons with type 2 diabetes mellitus (DM), but the effects on long‐term fracture risk are not known. The purpose of this Look AHEAD analysis was to evaluate whether long‐term intentional weight loss would increase fracture risk in overweight or obese persons with DM. Look AHEAD is a multicenter, randomized clinical trial. Recruitment began in August 2001 and follow‐up continued for a median of 11.3 years at 16 academic centers. A total of 5145 persons aged 45 to 76 years with DM were randomized to either an intensive lifestyle intervention (ILI) with reduced calorie consumption and increased physical activity designed to achieve and maintain ≥7% weight loss or to diabetes support and education intervention (DSE). Incident fractures were ascertained every 6 months by self‐report and confirmed with central adjudication of medical records. The baseline mean age of participants was 59 years, 60% were women, 63% were white, and the mean BMI was 36 kg/m2. Weight loss over the intervention period (median 9.6 years) was 6.0% in ILI and 3.5% in DSE. A total of 731 participants had a confirmed incident fracture (358 in DSE versus 373 in ILI). There were no statistically significant differences in incident total or hip fracture rates between the ILI and DSE groups. However, compared to the DSE group, the ILI group had a statistically significant 39% increased risk of a frailty fracture (HR 1.39; 95% CI, 1.02 to 1.89). An intensive lifestyle intervention resulting in long‐term weight loss in overweight/obese adults with DM was not associated with an overall increased risk of incident fracture but may be associated with an increased risk of frailty fracture. When intentional weight loss is planned, consideration of bone preservation and fracture prevention is warranted. © 2017 American Society for Bone and Mineral Research.


  • Open Access

    Polyphenol Levels Are Inversely Correlated with Body Weight and Obesity in an Elderly Population after 5 Years of Follow Up (The Randomised PREDIMED Study)

    by Xiaohui Guo, Anna Tresserra-Rimbau, Ramón Estruch, Miguel A. Martínez-González, Alexander Medina-Remón, Montserrat Fitó, Dolores Corella, Jordi Salas-Salvadó, Maria Puy Portillo, Juan J. Moreno, et al.

    Overweight and obesity have been steadily increasing in recent years and currently represent a serious threat to public health. Few human studies have investigated the relationship between polyphenol intake and body weight. Our aim was to assess the relationship between urinary polyphenol levels and body weight. A cross-sectional study was performed with 573 participants from the PREDIMED (Prevención con Dieta Mediterránea) trial (ISRCTN35739639). Total polyphenol levels were measured by a reliable biomarker, total urinary polyphenol excretion (TPE), determined by the Folin-Ciocalteu method in urine samples. Participants were categorized into five groups according to their TPE at the fifth year. Multiple linear regression models were used to assess the relationships between TPE and obesity parameters; body weight (BW), body mass index (BMI), waist circumference (WC), and waist-to-height ratio (WHtR). After a five years follow up, significant inverse correlations were observed between TPE at the 5th year and BW (β = −1.004; 95% CI: −1.634 to −0.375, p = 0.002), BMI (β = −0.320; 95% CI: −0.541 to −0.098, p = 0.005), WC (β = −0.742; 95% CI: −1.326 to −0.158, p = 0.013), and WHtR (β = −0.408; 95% CI: −0.788 to −0.028, p = 0.036) after adjustments for potential confounders. To conclude, a greater polyphenol intake may thus contribute to reducing body weight in elderly people at high cardiovascular risk.


  • Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders

    by Xavier Pi-Sunyer, William Shanahan, Randi Fain, Tony Ma, W. Timothy Garvey

    Objectives: Treatment guidelines for type 2 diabetes mellitus (T2DM) suggest weight loss as a means to maintain glycemic control. Lorcaserin has been approved for chronic weight management in the United States as an adjunct to a reduced-calorie diet and exercise, and the previous phase 3 Behavioral Modification and Lorcaserin for Obesity and Overweight Management in Diabetes Mellitus (BLOOM-DM) study has shown that, in addition to weight loss, lorcaserin is associated with improvements in glycemic parameters. In this post hoc analysis of the BLOOM-DM trial, the relationship between responder status (patients achieving 5% weight loss at Week 52) and glycemic and cardiometabolic parameters is evaluated.Methods: Data are presented for patients receiving lorcaserin 10mg twice daily or placebo for 52 weeks.Results: More than twice as many patients receiving lorcaserin plus diet and exercise counseling were classified as Week 52 responders compared to those receiving diet and exercise counseling alone (37.5% vs. 16.1%, respectively; p<0.001), and lorcaserin Week 52 responders had greater improvements vs. placebo Week 52 responders in FPG (-38.1mg/dL vs. -26.0mg/dL) and HbA1c (-1.3% vs. -1.0%). Furthermore, more lorcaserin-treated Week 52 responders decreased the number of concomitant oral antidiabetic medications (OADs) used, and fewer increased the number of OADs used, compared to placebo. Unexpectedly, lorcaserin Week 52 nonresponders also had substantial reductions in glycemic levels, despite very modest weight loss.Conclusions: These data support lorcaserin use in overweight and obese patients with T2DM to promote weight loss and facilitate glycemic control.Clinical trial registration: www.clinicaltrials.gov identifier is NCT00603291


  • Open Access

    The Rationale, Feasibility, and Optimal Training of the Non-Physician Medical Nutrition Scientist

    by Susan E. Ettinger, Jennifer A. Nasser, Ellen S. Engelson, Jeanine B. Albu, Sami Hashim, F. Xavier Pi-Sunyer

    Dietary components have potential to arrest or modify chronic disease processes including obesity, cancer, and comorbidities. However, clinical research to translate mechanistic nutrition data into clinical interventions is needed. We have developed a one-year transitional postdoctoral curriculum to prepare nutrition scientists in the language and practice of medicine and in clinical research methodology before undertaking independent research. Candidates with an earned doctorate in nutrition science receive intensive, didactic training at the interface of nutrition and medicine, participate in supervised medical observerships, and join ongoing clinical research. To date, we have trained four postdoctoral fellows. Formative evaluation revealed several learning barriers to this training, including deficits in prior medical science knowledge and diverse perceptions of the role of the translational nutrition scientist. Several innovative techniques to address these barriers are discussed. We propose the fact that this train the trainer approach has potential to create a new translational nutrition researcher competent to identify clinical problems, collaborate with clinicians and researchers, and incorporate nutrition science across disciplines from bench to bedside. We also expect the translational nutrition scientist to serve as an expert resource to the medical team in use of nutrition as adjuvant therapy for the prevention and management of chronic disease. Dietary components have potential to arrest or modify chronic disease processes including obesity, cancer, and comorbidities. However, clinical research to translate mechanistic nutrition data into clinical interventions is needed. We have developed a one-year transitional postdoctoral curriculum to prepare nutrition scientists in the language and practice of medicine and in clinical research methodology before undertaking independent research. Candidates with an earned doctorate in nutrition science receive intensive, didactic training at the interface of nutrition and medicine, participate in supervised medical observerships, and join ongoing clinical research. To date, we have trained four postdoctoral fellows. Formative evaluation revealed several learning barriers to this training, including deficits in prior medical science knowledge and diverse perceptions of the role of the translational nutrition scientist. Several innovative techniques to address these barriers are discussed. We propose the fact that this train the trainer approach has potential to create a new translational nutrition researcher competent to identify clinical problems, collaborate with clinicians and researchers, and incorporate nutrition science across disciplines from bench to bedside. We also expect the translational nutrition scientist to serve as an expert resource to the medical team in use of nutrition as adjuvant therapy for the prevention and management of chronic disease.


  • The Look AHEAD Trial: A Review and Discussion of Its Outcomes

    by Xavier Pi-Sunyer

    The Look AHEAD trial was a randomized controlled trial comparing an intensive lifestyle intervention (ILI) to diabetes support and education (DSE) in overweight and obese type 2 diabetes patients to track the development of cardiovascular disease over time. The triaI intervention was stopped for futility after a median follow-up of 9.6 years. While there was a differential effect on weight loss and fitness between the two groups, there was no effect on cardiovascular outcomes. Cardiovascular events were less than half the projected rate per year in the DSE group, thus there was a very low overall rate of events in both groups. There were many other health benefits of ILI, including improved biomarkers of glucose and lipid control, less sleep apnea, lower liver fat, less depression, improved insulin sensitivity, less urinary incontinence, less kidney disease, reduced need of diabetes medications, maintenance of physical mobility, improved quality of life, and lower costs.


  • Coffee consumption is inversely associated with type 2 diabetes in Chinese

    by Wen‐Yuan Lin, F. Xaiver Pi‐Sunyer, Ching‐Chu Chen, Lance E. Davidson, Chiu‐Shong Liu, Tsai‐Chung Li, Mei‐Fong Wu, Chia‐Ing Li, Walter Chen, Cheng‐Chieh Lin

    Eur J Clin Invest 2011; 41 (6): 659–666 Background  Coffee consumption has been shown to be inversely associated to type 2 diabetes mellitus (T2DM), but evidence in Chinese populations is limited. We investigated the relationship between coffee consumption and T2DM in a population‐based cohort of middle‐aged Chinese.Materials and methods  We studied 2332 subjects who participated in the Taichung Community Health Study in Taiwan in 2004. The relationships between coffee consumption, T2DM and fasting glucose were assessed.Results  The prevalence of T2DM was 14·0% and 10·4% in men and women. After adjustment for age, body mass index, blood pressure, smoking, alcohol drinking, betel nut chewing, physical activity, income, education level, fat%, protein%, carbohydrate% and magnesium, coffee intake was inversely associated with T2DM. Habitual coffee drinkers had 38–46% lower risk of T2DM than nondrinkers. Compared to nondrinkers, the adjusted odds ratios (ORs) for T2DM according to subjects with habitual coffee consumption (< 1, 1–6, ≥ 7 times per week) were 0·77 (0·52–1·13), 0·46 (0·28–0·76) and 0·37 (0·16–0·83), respectively. The decreasing ORs indicate a dose–response effect of coffee consumption on the likelihood of having T2DM (P < 0·001). A similar relationship was also evident in newly diagnosed T2DM (P < 0·05). The adjusted mean fasting glucose levels gradually decreased as the frequency of coffee consumption increased (P < 0·05).Conclusions  Coffee intake is inversely associated with T2DM in Chinese. Coffee may be a protective agent for T2DM in Chinese.


  • Open Access

    Glycemic index in early type 2 diabetes

    by Xavier Pi-Sunyer

    In this issue of the Journal, Wolever et al (1) report the results of the Canadian Trial of Carbohydrates in Diabetes. This is an interesting report comparing the effects of high- and low-glycemic-index (GI) diets with those of a low-carbohydrate diet on various metabolic markers of disease. The bottom line is that following these 3 diets for 1 y produced essentially no difference in the subject groups with respect to glycated hemoglobin (HbA1c), lipids, or insulin. As reported in a recent Cochrane review (2), few to no high-quality long-term data are available on the dietary treatment of type 2 diabetes mellitus. Therefore, a well-carried-out, extended study such as that of Wolever et al is very welcome, and, from it, several interesting observations emerge.


  • The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight

    by F Xavier Pi-Sunyer

    Type 2 diabetes mellitus and obesity share a pathogenic relationship, and both have rapidly increased in prevalence over the past decade. This review evaluates the effects of antidiabetes therapies on weight and glycemic control in the type 2 diabetes mellitus population. A PubMed search was conducted to identify randomized controlled trials that reported the weight effects of antidiabetes treatments. The search focused on the newer incretin-based therapies, including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) agonists. Antiobesity drugs and treatment options potentially available to patients with type 2 diabetes mellitus, including bariatric surgery, were also examined. Most of the established antidiabetes therapies (eg, sulfonylureas, thiazolidinediones) promote weight gain, thereby exacerbating insulin resistance and glucose intolerance. Dipeptidyl peptidase-4 inhibitors exhibit a weight-neutral profile, however, and GLP-1 receptor agonists (eg, exenatide, liraglutide) have achieved significant body weight reductions in spite of improved glycemic control, which is often accompanied by weight gain. Antiobesity drugs, such as orlistat and sibutramine, are effective weight-lowering agents in patients with type 2 diabetes mellitus, but safety and tolerability concerns may limit their use. Bariatric surgery in obese patients is associated with improved glycemic values and decreased mortality. Clinical evidence substantiating the weight-neutral effects of DPP-4 inhibitors and the weight-loss effects of GLP-1 agonists is promising, offering an expansion of therapeutic options for overweight and obese patients with type 2 diabetes mellitus. Evidence on the clinical utility of antiobesity drugs is more equivocal, and more data are needed to evaluate the safety and tolerability of these agents.


  • Open Access

    Comparisons of Body Volumes and Dimensions Using Three-Dimensional Photonic Scanning in Adult Hispanic-Americans and Caucasian-Americans

    by Josefina Olivares, Jack Wang, Wen Yu, Vicente Pereg, Richard Weil, Betty Kovacs, Dympna Gallagher, F. Xavier Pi-Sunyer

    Background: We studied whether significant differences exist between Hispanic-Americans (H-A) and Caucasian-Americans (C-A) in body dimensions using a newly validated three-dimensional photonic scanner (3DPS). Methods: We compared two cohorts of 34 adult U.S.-based H-A (19 females) and 40 adult C-A (25 females) of similar age and body mass index (BMI, kg/m2). We measured total body volume (TBV), trunk volume (TV), and other body dimensions, including waist and hip circumferences, estimated percentage body fat (%fat), calculated TV/TBV, and waist-to-hip ratio. Results: For female cohorts, there were no significant differences in age, weight, height, and 3DPS-measured variables between the two ethnic cohorts. For male cohorts, C-A had greater height ( p = 0.014), but there were no significant differences in absolute or proportional volumes or dimensions between the two cohorts. Conclusions: Results demonstrate that, in these H-A and C-A cohorts of similar age and BMI, total and regional body volumes and dimensions, as well as their proportions, approximate each other very closely in both sexes; these variables also show similar relationships with %fat in each sex. This is in contradistinction to previous study reports using other measurement techniques.